Boston Scientific Corporation (NYSE:BSX) EVP Michael P. Phalen sold 15,500 shares of the stock in a transaction on Friday, September 29th. The stock was sold at an average price of $28.72, for a total transaction of $445,160.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Michael P. Phalen also recently made the following trade(s):

  • On Tuesday, August 29th, Michael P. Phalen sold 15,500 shares of Boston Scientific Corporation stock. The shares were sold at an average price of $26.87, for a total transaction of $416,485.00.
  • On Monday, July 31st, Michael P. Phalen sold 15,500 shares of Boston Scientific Corporation stock. The stock was sold at an average price of $27.13, for a total transaction of $420,515.00.

Boston Scientific Corporation (NYSE:BSX) opened at 29.02 on Wednesday. Boston Scientific Corporation has a 12 month low of $19.67 and a 12 month high of $29.50. The stock’s 50 day moving average is $28.06 and its 200 day moving average is $26.92. The company has a market cap of $39.82 billion, a PE ratio of 51.91 and a beta of 1.09.

Boston Scientific Corporation (NYSE:BSX) last posted its quarterly earnings data on Thursday, July 27th. The medical equipment provider reported $0.32 earnings per share for the quarter, beating the consensus estimate of $0.31 by $0.01. Boston Scientific Corporation had a return on equity of 23.62% and a net margin of 9.04%. The company had revenue of $2.26 billion during the quarter, compared to analysts’ expectations of $2.21 billion. Boston Scientific Corporation’s revenue for the quarter was up 6.2% compared to the same quarter last year. During the same period in the prior year, the business earned $0.27 earnings per share. Equities analysts predict that Boston Scientific Corporation will post $1.26 earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: This report was originally published by Marea Informative and is the sole property of of Marea Informative. If you are reading this report on another domain, it was illegally stolen and republished in violation of international copyright & trademark laws. The legal version of this report can be viewed at http://www.mareainformativa.com/michael-p-phalen-sells-15500-shares-of-boston-scientific-corporation-bsx-stock/115633/.

A number of large investors have recently added to or reduced their stakes in the stock. UBS Asset Management Americas Inc. grew its position in Boston Scientific Corporation by 9.1% in the 1st quarter. UBS Asset Management Americas Inc. now owns 3,435,806 shares of the medical equipment provider’s stock worth $85,448,000 after purchasing an additional 286,705 shares during the last quarter. Baird Financial Group Inc. bought a new position in shares of Boston Scientific Corporation during the 1st quarter worth about $293,000. Raymond James Financial Services Advisors Inc. increased its holdings in shares of Boston Scientific Corporation by 12.0% during the 1st quarter. Raymond James Financial Services Advisors Inc. now owns 43,318 shares of the medical equipment provider’s stock worth $1,077,000 after purchasing an additional 4,657 shares during the period. Los Angeles Capital Management & Equity Research Inc. bought a new position in shares of Boston Scientific Corporation during the 1st quarter worth about $215,000. Finally, Schroder Investment Management Group increased its holdings in shares of Boston Scientific Corporation by 17.6% during the 1st quarter. Schroder Investment Management Group now owns 266,557 shares of the medical equipment provider’s stock worth $6,517,000 after purchasing an additional 39,931 shares during the period. Hedge funds and other institutional investors own 90.44% of the company’s stock.

BSX has been the subject of several recent research reports. Stifel Nicolaus reiterated a “buy” rating and issued a $32.00 price target on shares of Boston Scientific Corporation in a report on Sunday, July 30th. J P Morgan Chase & Co restated an “overweight” rating and set a $31.00 price objective (up previously from $27.00) on shares of Boston Scientific Corporation in a research note on Wednesday, June 28th. Jefferies Group LLC restated a “hold” rating on shares of Boston Scientific Corporation in a research note on Thursday, September 7th. Royal Bank Of Canada reaffirmed a “buy” rating and issued a $31.00 target price on shares of Boston Scientific Corporation in a research report on Friday, September 1st. Finally, BidaskClub downgraded Boston Scientific Corporation from a “strong-buy” rating to a “buy” rating in a research report on Thursday, July 6th. One analyst has rated the stock with a sell rating, five have issued a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $30.12.

Boston Scientific Corporation Company Profile

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.

Insider Buying and Selling by Quarter for Boston Scientific Corporation (NYSE:BSX)

Receive News & Stock Ratings for Boston Scientific Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific Corporation and related stocks with our FREE daily email newsletter.